03:17 , Nov 17, 2018 |  BioCentury  |  Product Development

Rethinking RECIST for immunotherapies

Momentum is growing for new tumor response criteria that better reflect the benefits of cancer immunotherapies, with FNIH, companies and FDA all pushing for validation of these criteria. At a Nov. 9 workshop co-hosted by...
19:27 , Nov 16, 2018 |  BC Week In Review  |  WIR Deals New Deals

Boehringer, Epizyme to develop small molecules against epigenetic cancer targets

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with Epizyme Inc. (NASDAQ:EPZM) to develop small molecule inhibitors of two undisclosed epigenetic cancer targets in the helicase and histone acetyltransferase (HAT) families. The companies plan to focus on...
16:04 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

AZ’s Farxiga reduces heart failure, but misses on CV events

AstraZeneca plc (LSE:AZN; NYSE:AZN) presented details of its 17,160-patient Phase III DECLARE-TIMI 58 cardiovascular outcomes trial (CVOT) showing that diabetes drug Farxiga dapagliflozin's primary CV benefit was limited to reducing hospitalizations due to heart failure....
15:58 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Swiss cancer play Amal eyes clinic following €21.2M tranche

Cancer vaccine company Amal Therapeutics S.A. (Geneva, Switzerland) closed the second and final tranche of its series B round at €21.2 million ($24 million), bringing the total amount raised in the round to €29 million...
23:23 , Nov 15, 2018 |  BC Extra  |  Company News

Boehringer, Epizyme to develop small molecules against epigenetic cancer targets

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with Epizyme Inc. (NASDAQ:EPZM) to develop small molecule inhibitors of two undisclosed epigenetic cancer targets in the helicase and histone acetyltransferase (HAT) families. The companies plan to focus on...
23:47 , Nov 12, 2018 |  BC Extra  |  Clinical News

AZ’s Farxiga reduces heart failure, but misses on CV events

AstraZeneca plc (LSE:AZN; NYSE:AZN) presented details of its 17,160-patient Phase III DECLARE-TIMI 58 cardiovascular outcomes trial (CVOT) showing that diabetes drug Farxiga dapagliflozin's primary CV benefit was limited to reducing hospitalizations due to heart failure....
10:56 , Nov 12, 2018 |  BC Extra  |  Financial News

Swiss cancer play Amal eyes clinic following €21.2M tranche

Cancer vaccine company Amal Therapeutics S.A. (Geneva, Switzerland) closed the second and final tranche of its series B round at €21.2 million ($24 million), bringing the total amount raised in the round to €29 million...
22:54 , Nov 9, 2018 |  BioCentury  |  Product Development

Cashing out CVOT

Whether or how much diabetes companies will save by dropping postmarket cardiovascular outcomes trials, if FDA follows the advice of its advisory committee, could boil down to what target they are pursuing and whether they...
18:31 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Sandoz gives up on Rituxan biosimilar in U.S.

With two competing biosimilars under FDA review, Sandoz will no longer seek U.S. approval of GP2013, its biosimilar of cancer and autoimmune drug Rituxan/MabThera rituximab from Roche (SIX:ROG; OTCQX:RHHBY). The unit of Novartis AG (NYSE:NVS;...
04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....